Importance of daily plasma glucose control in type 2 diabetes

Journal of Family Practice

Volumn 58, Issue 8 SUPPL., 2009, Pages

  Pollom, Roy Daniel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

ADD ON THERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIABETES MELLITUS; DIET RESTRICTION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG SUBSTITUTION; EVENING DOSAGE; EXERCISE; GENETIC SUSCEPTIBILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN PEN; INSULIN PUMP; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; MORNING DOSAGE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PROLIFERATIVE RETINOPATHY; REVIEW; SELF MONITORING; SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN INFUSION SYSTEMS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 68349097554     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med. 2008;121(Suppl):S9-S19. (Pubitemid 351726334)
2. Phillips P. Insulins in 2002. Australian Prescriber. 2002;25:29-31.
3. Muoio DM, Newgard CB. Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:I93-205.
4. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Médeau V, Kevorkian IP. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 2008;34(Suppl 2):S43-S48. (Pubitemid 351982036)
5. Lupi R, Del Prato S. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences. Diabetes Metab. 2008;34 (Suppl 2):S56-S64. (Pubitemid 351978285)
6. Robertson RP, Olson LK, Zhang HJ. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes. 1994;43:1085-1089. (Pubitemid 124005172)
7. Matveyenko AV, Butler PC. Relationship between beta-cell mass and diabetes onset. Diabetes Obes Metab. 2008;10 (Suppl 4):23-31.
8. Thamer C, Haap M, Heller E, et al. Beta cell function, insulin resistance and plasma adiponectin concentrations are predictors for the change of postprandial glucose in non-diabetic subjects at risk for type 2 diabetes. Horm Metab Res. 2006;38:178-182.
9. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822-1826. (Pubitemid 27522889)
10. Rohlfing CL, Wiedmeyer HM, Little RR, England ID, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA1c. Analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275-278.
11. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Variations with increasing levels of HbA1c. Diabetes Care. 2003;26:881-885.
12. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
13. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353:2643-2653. (Pubitemid 41817713)
14. Tanne D, Koren-Morag N, Goldbourt U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study. Stroke. 2004;35:2351-2355. (Pubitemid 39311262)
15. Gerstein HC, Pogue J, Mann IF, Lonn E, Dagenais GR, McQueen M, et al, for the HOPE Investigators. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005;48:1749-1755.
16. Iseki K, Ikemiya Y, Kinjo K, Iseki C, Takishita S. Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan. Clin Exp Nephrol. 2004;8:250-256.
17. Fuller JH, Stevens LK, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44 (Suppl 2):S54-S64.
18. Nazimek-Siewniak B, Moczulski D, Grzeszczak W. Risk of macrovascular and microvascular complications in type 2 diabetes: results of longitudinal study design. J Diabetes Complications. 2002;16:271-276. (Pubitemid 34765725)
19. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet. 1999;354:617-621.
20. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation. 1995;91:2591-2595.
21. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel, et al, for the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
22. Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab. 2006;91:813-819. (Pubitemid 43357744)
23. Gerich JE, Odawara M, Terauchi Y. The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk. Curr Med Res Opin. 2007;23:1791-1798. (Pubitemid 47300377)
24. Monnier L, Colette C. Glycemic variability. Should we and can we prevent it? Diabetes Care. 2008;31(Suppl 2):S150-S154.
25. Gordin D, Rönnback M, Forsblom C, Mäkinen V, Saraheimo M, Groop PH. Glucose variability, blood pressure and arterial stiffness in type 1 diabetes. Diabetes Res Clin Pract. 2008;80:e4-e7.
26. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
27. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next? Diabetes Metab Res Rev. 2007;23:257-264.
28. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diab Obes Metab. 2007;9:31-38. (Pubitemid 44921039)
29. Rosenstock I, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008;51:408-416.
30. Rosenstock J. Basal insulin supplementation in type 2 diabetes: refining the tactics. Am J Med. 2004;116(Suppl):10S-16S. (Pubitemid 38167752)
31. Tîrgoviste CI, Strachinariu R, Farcasiu E, Milicevic Z, Teodorescu G. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Rom J Intern Med. 2003;41:153-162.
32. Raskin P, Matfin G, Schwartz SL, et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes Obes Metab. 2009;11:27-32.
33. Qayyum R, Bolen S, Maruthur N, Feldman L, Wilson LM, Marinopoulos SS, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008;149:549-559.
34. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. J Endocrinol Invest. 2009;32:23-27.
35. Hermansen K, Colombo M, Storgaard H, ØStergaard A, Kølendorf K, Madsbad S. Improved post-prandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002;25:883-888.
36. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The I-2-3 study). Diabetes Obes Metab. 2006;8:58-66.
37. Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab. 2006;32:7-13. (Pubitemid 43872590)
38. DeWitt DE, Dugdale DC. Common problems in outpatient management of patients with diabetes in the age of insulin analogues. Prim Care Clin Office Pract. 2003;30:543-556.
39. Rabasa-Lhoret R, Bourque J, Ducros F, Chiasson JL. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care. 2001;24:625-630. (Pubitemid 32888838)
40. King AB, Armstrong DU. Basal bolus dosing: a clinical experience. Curr Diabetes Rev. 2005;1:215-220.
41. Davis NJ, Wylie-Rosett J. Death to carbohydrate counting? Diabetes Care. 2008;31:1467-1468.
42. Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, et al. Adjust to target in type 2 diabetes. Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 2008;31:1305-1310.
43. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther. 2008;10:247-256.
44. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson PC. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev. 2002;18(Suppl 1):S14-S20. (Pubitemid 34411296)
45. Wittlin SD. Treating the spectrum of type 2 diabetes: emphasis on insulin pump therapy. Diabetes Educ. 2006;32 (Suppl):39S-46S.
46. Berthe E, Lireux B, Coffin C, Goulet-Salmon B, Houlbert D, Boutreux S, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res. 2007;39:224-229. (Pubitemid 46580623)
47. Chlup R, Zapletalová J, Seckar P, Chlupová L, Táncosová S, Reznícková M. Benefits of insulin aspart vs phosphate-buffered human regular insulin in persons with type 1 diabetes treated by means of an insulin pump. Biomed Paper. 2004;148:27-32.
48. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care. 2003;26:2598-2603. (Pubitemid 37052106)
49. Cogen FR, Streisand R, Sarin S. Selecting children and adolescents for insulin pump therapy: medical and behavioral considerations. Diab Spectrum. 2002;15:72-75.
50. Hirsch IB, Abelseth J, Bode BW, et al. Sensor-augmented insulin pump therapy, results of the first randomized treat-to-target study. Diabetes Technol Ther. 2008;10:377-383.
51. Lougheed WD, Zinman B, Strack TR, et al. Stability of insulin lispro in insulin infusion systems. Diabetes Care. 1997;20:1061-1065. (Pubitemid 27274263)
52. DeFelippis MR, Bell MA, Heyob JA, Storms SM. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther. 2006;8:358-368.
53. Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care. 1998;21:817-821. (Pubitemid 28487078)